417717-04-5

Basic information

• Product Name: Lenvatinib Impurity d
• Synonyms: Lenvatinib Impurity d;4-(3-chloro-4-(3-cyclopropylureido)phenoxy)-7-hydroxyquinoline-6-carboxamide
• CAS NO: 417717-04-5
• Molecular Formula: C₂₀H₁₇ClN₄O₄
• Molecular Weight: 412.82638
• Mol File: 417717-04-5.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 644.1±55.0 °C(Predicted)
• Appearance: /
• Density: 1.55±0.1 g/cm3(Predicted)
• PKA: 4.49±0.40(Predicted)
• CAS DataBase Reference: Lenvatinib Impurity d(CAS DataBase Reference)
• NIST Chemistry Reference: Lenvatinib Impurity d(417717-04-5)
• EPA Substance Registry System: Lenvatinib Impurity d(417717-04-5)

Safety Data

• Hazardous Substances Data: 417717-04-5(Hazardous Substances Data)

Usage

Uses

O-Demethyl Lenvatinib is a metabolite of Lenvatinib (L329400) which is an orally active inhibitor of multiple receptor tyrosine kinases including VEGF, FGF and SCF receptors.

Upstream product

• 417716-92-8 lenvatinib 
• 417717-03-4 7-Benzyloxy-4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-6-quinolinecarboxamide 

Downstream Products

• 417717-11-4 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(3-hydroxypropoxy)-6-quinolinecarboxamide 
• 417717-10-3 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-hydroxyethoxy)-6-quinolinecarboxamide 
• 417717-05-6 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide 
• 417719-56-3 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-ethoxyethoxy)-6-quinolinecarboxamide 
• 417719-57-4 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-cyclopropylmethoxy-6-quinolinecarboxamide 

Relevant articles and documents

QUINOLYL-CONTAINING COMPOUND AND PHARMACEUTICAL COMPOSITION, AND USE THEREOF

Provided is a quinolyl-containing compound as shown in general formula (I) or (II) or a pharmaceutically acceptable salt, a solvate, an active metabolite, a polymorph, an isotopic label, or an isomer thereof, and further provided are a pharmaceutical composition comprising the compound and use of the compound and the pharmaceutical composition. The provided compound has a dual molecule function, can serve as multi -target inhibitors of novel tyrosine kinase/histone deacetylase, can simultaneously achieve the effect of two inhibitors, has excellent biological activity and pharmacokinetic properties, and has the application potential particularly in the field of treatment of tumors.